A Phase 2 interventional study of AZD2389 in Liver Fibrosis and Hepatic Cirrhosis, sponsored by AstraZeneca. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.
Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 6th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 2, and was the 6th registered.
1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 40 across the 11 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
1 of the studies in Liver Cirrhosis by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07610837AstraZenecaStudy of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | 2027-07-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Liver Cirrhosis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
Study details include:
The study duration will be up to 63 days (9 weeks).
Number of Participants:
The study will randomise approximately 36 participants in total. Cohort A: Approximately 75 participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. Cohort B: Approximately 75 participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo
Key inclusions:
Key exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.
Drug: AZD2389
Participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.
Drug: AZD2389
Doses of AZD2389 or placebo will be administered orally.
Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)
The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria.
Time frame: From screening up to and including Day 35
Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)
The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities.
Time frame: From Screening up to and including Day 35
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Cmax
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Cmax= Maximum Concentration
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Tmax
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. tmax = Time to Maximum Concentration
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: t1/2 Lambda z
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. t1/2 lambda z= Apparent Terminal Half-life
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: AUClast, AUCinf, and AUCtau
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. AUClast= Area Under the Concentration-time Curve to the Last Measurable Concentration AUCinf = Area Under the Concentration-time Curve Extrapolated to Infinity AUCtau = Area Under the Concentration-time Curve Over a Dosing Interval AUCtau presented as AUC(0-24h) in the table. In line with standard PK analysis methodologies, AUCinf was estimated only for Day 1. AUClast and AUCtau were estimated for both Day 1 and Day 28.
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Lambda z
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. lambda z = Terminal elimination rate constant
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Vz/F
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Vz/F = Apparent Volume of Distribution
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: CL/F and CLR
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. CL/F = Apparent Clearance CLR = Renal Clearance
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. TCP is calculated as the ratio of steady-state AUCtau (AUC0-24h) to first-dose AUCinf TCP = Temporal Change Parameter AUC = Area Under the Concentration-time Curve
Time frame: Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Rac AUC and Rac Cmax
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Rac AUC = AUC Accumulation Ratio; ratio of steady state AUCtau (AUC0-24h)/First Dose AUCtau (AUC0-24h) Rac Cmax = Cmax Accumulation Ratio; ratio of steady state Cmax/First Dose Cmax
Time frame: Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Ae (0-24)
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Ae (0-24) = Cumulative Amount of Drug Excreted Unchanged in Urine
Time frame: Day 1 and Day 28
Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: Fe (0-24)
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Fe = Fraction of Dose Excreted Unchanged into Urine
Time frame: Day 1 and Day 28
Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo.
Effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with chronic Liver Disease and hepatic fibrosis was evaluated and presented as percentage change from baseline in FAP activity. Percentage change when comparing post-treatment visits to baseline for each group, calculated as (Geometric LS mean - 1) \*100. FAP=Fibroblast Activating Protein
Time frame: Day 28
A total of 95 participants were screened for the study at 9 centres (1 in the UK and 8 in the US).
| Milestone | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Started | 14 | 8 | 12 | 6 |
| Completed | 14 | 8 | 12 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Cmax= Maximum Concentration
| nmol/L | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Day 1 | 2045 ± 57.39 | — | 1902 ± 47.63 | — |
| Day 28 | 1884 ± 60.65 | — | 1730 ± 63.54 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. tmax = Time to Maximum Concentration
| hour | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Day 1 | 1.00 (0.50 to 4.00) | — | 1.00 (0.50 to 4.00) | — |
| Day 28 | 1.00 (0.50 to 4.00) | — | 1.00 (0.50 to 2.00) | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. t1/2 lambda z= Apparent Terminal Half-life
| hour | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Day 1 | 3.801 ± 36.42 | — | 5.545 ± 58.67 | — |
| Day 28 | 5.331 ± 57.86 | — | 5.527 ± 64.06 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. AUClast= Area Under the Concentration-time Curve to the Last Measurable Concentration AUCinf = Area Under the Concentration-time Curve Extrapolated to Infinity AUCtau = Area Under the Concentration-time Curve Over a Dosing Interval AUCtau presented as AUC(0-24h) in the table. In line with standard PK analysis methodologies, AUCinf was estimated only for Day 1. AUClast and AUCtau were estimated for both Day 1 and Day 28.
| h*nmol/L | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| AUClast: Day 1 | 7339 ± 42.79 | — | 6052 ± 32.89 | — |
| AUClast: Day 28 | 7529 ± 51.51 | — | 5482 ± 34.29 | — |
| AUCinf: Day 1 | 7409 ± 42.88 | — | 6480 ± 39.06 | — |
| AUC0-24h: Day 1 | 7341 ± 42.76 | — | 6112 ± 32.58 | — |
| AUC0-24h: Day 28 | 7301 ± 48.45 | — | 5374 ± 33.20 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. lambda z = Terminal elimination rate constant
| 1/h | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Day 1 | 0.1824 ± 36.42 | — | 0.1250 ± 58.67 | — |
| Day 28 | 0.1300 ± 57.86 | — | 0.1254 ± 64.06 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Vz/F = Apparent Volume of Distribution
| L | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Day 1 | 215.8 ± 44.25 | — | 360.0 ± 44.45 | — |
| Day 28 | 307.2 ± 84.33 | — | 432.8 ± 68.96 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. CL/F = Apparent Clearance CLR = Renal Clearance
| L/h | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| CL/F: Day 1 | 39.36 ± 42.88 | — | 45.00 ± 39.06 | — |
| CL/F: Day 28 | 39.95 ± 48.45 | — | 54.27 ± 33.20 | — |
| CLR: Day 1 | 8.492 ± 231.5 | — | 16.41 ± 35.30 | — |
| CLR: Day 28 | 11.13 ± 75.23 | — | 17.05 ± 194.2 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. TCP is calculated as the ratio of steady-state AUCtau (AUC0-24h) to first-dose AUCinf TCP = Temporal Change Parameter AUC = Area Under the Concentration-time Curve
| Ratio | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Plasma and Urine Pharmacokinetic (PK) Parameters of AZD2389: TCP AUC | 0.9853 ± 28.59 | — | 0.8293 ± 61.87 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Rac AUC = AUC Accumulation Ratio; ratio of steady state AUCtau (AUC0-24h)/First Dose AUCtau (AUC0-24h) Rac Cmax = Cmax Accumulation Ratio; ratio of steady state Cmax/First Dose Cmax
| Ratio | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Rac AUC: Day 28 | 0.9945 ± 28.76 | — | 0.8792 ± 54.94 | — |
| Rac Cmax: Day 28 | 0.9212 ± 40.86 | — | 0.9095 ± 72.69 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Ae (0-24) = Cumulative Amount of Drug Excreted Unchanged in Urine
| mg | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Day 1 | 22.53 ± 257.8 | — | 37.35 ± 33.89 | — |
| Day 28 | 30.81 ± 95.26 | — | 26.89 ± 100.5 | — |
The PK of AZD2389 were evaluated following oral dosing in Cohort A and Cohort B and presented in table. Fe = Fraction of Dose Excreted Unchanged into Urine
| % of fraction of dose unchanged | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Day 1 | 18.78 ± 257.8 | — | 31.12 ± 33.89 | — |
| Day 28 | 25.67 ± 95.26 | — | 22.41 ± 100.5 | — |
The number of participants with notable trends in laboratory assessments (haematology, coagulation, clinical chemistry, fibrinolysis, and urinalysis) is presented. Notable trends were assessed based on evaluation of mean values over time, individual participant values, and clinically important abnormalities, including values outside predefined criteria.
| Participants | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis) | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
The number of participants with clinically relevant trends in vital signs (blood pressure, pulse rate, oxygen saturation, body temperature, and respiration rate), and12-lead ECGs is presented. Clinically relevant trends were assessed based on trends or group changes over time, changes in individual participants over time, and individual clinically important abnormalities.
| Participants | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG) | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
Effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with chronic Liver Disease and hepatic fibrosis was evaluated and presented as percentage change from baseline in FAP activity. Percentage change when comparing post-treatment visits to baseline for each group, calculated as (Geometric LS mean - 1) \*100. FAP=Fibroblast Activating Protein
| % of change in FAP activity | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| Inhibition of FAP Activity Calculated as Percentage Change in FAP Activity Against Baseline Compared to Placebo. | -80.0122 (-87.6644 to -67.6131) | 10.3140 (-43.5942 to 115.7436) | -83.3455 (-91.2626 to -68.2546) | -10.3764 (-64.0341 to 123.3336) |
Collected over From screening to Day 35 up to 63 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A - AZD2389 | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| Cohort A - Placebo | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Cohort B - AZD2389 | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Cohort B - Placebo | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo |
|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/14 | 0/8 | 0/12 | 1/6 |
| Electrocardiogram qt prolongedInvestigations | 0/14 | 1/8 | 0/12 | 0/6 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/14 | 1/8 | 0/12 | 0/6 |
| VomitingGastrointestinal disorders | 0/14 | 1/8 | 0/12 | 0/6 |
| RhinitisInfections and infestations | 0/14 | 1/8 | 0/12 | 0/6 |
| Blood creatine phosphokinase increasedInvestigations | 0/14 | 0/8 | 1/12 | 0/6 |
| HeadacheNervous system disorders | 1/14 | 0/8 | 0/12 | 0/6 |
| DysuriaRenal and urinary disorders | 1/14 | 0/8 | 0/12 | 0/6 |
| PruritusSkin and subcutaneous tissue disorders | 1/14 | 0/8 | 0/12 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/14 | 0/8 | 0/12 | 0/6 |
| Age, Continuous(years) | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo | Total |
|---|---|---|---|---|---|
| Mean | 58.9 ± 12.8 | 57.5 ± 10.2 | 54.8 ± 7.1 | 55.5 ± 10.2 | 56.9 ± 10.2 |
| Age, Customized(Participants) | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo | Total |
|---|---|---|---|---|---|
| 18 - < 65 | 8 | 6 | 12 | 4 | 30 |
| >= 65 | 6 | 2 | 0 | 2 | 10 |
| Sex: Female, Male(Participants) | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo | Total |
|---|---|---|---|---|---|
| Female | 7 | 4 | 2 | 4 | 17 |
| Male | 7 | 4 | 10 | 2 | 23 |
| Race/Ethnicity, Customized(Participants) | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 11 | 6 | 34 |
| Not Hispanic or Latino | 5 | 0 | 1 | 0 | 6 |
| Race/Ethnicity, Customized(Participants) | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 0 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Not reported | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 |
| White | 13 | 8 | 10 | 6 | 37 |
| Region of Enrollment(Participants) | Cohort A - AZD2389 | Cohort A - Placebo | Cohort B - AZD2389 | Cohort B - Placebo | Total |
|---|---|---|---|---|---|
| USA | 14 | 8 | 12 | 6 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Dec 2024 to primary completion in Jul 2025, 7 months.
Results were first posted in Jul 2026, 11 months after primary completion.
Of 28 industry-sponsored phase 2 interventional studies under Liver Cirrhosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's 7 months is below that.
Counting every sponsor, half of 55 studies reached it within 27 months; a quarter within 19 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD2389